These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 30106434

  • 1. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Alsamman K, El-Masry OS.
    Oncol Rep; 2018 Oct; 40(4):2157-2162. PubMed ID: 30106434
    [Abstract] [Full Text] [Related]

  • 2. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
    Nguyen EV, Huhtinen K, Goo YA, Kaipio K, Andersson N, Rantanen V, Hynninen J, Lahesmaa R, Carpen O, Goodlett DR.
    Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L, Xu F, Kong Q, Yang T, Tan D, Zhang X, Li N, Zhao S, Zhao J, Li M.
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [Abstract] [Full Text] [Related]

  • 4. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation.
    Battista RA, Resnati M, Facchi C, Ruggieri E, Cremasco F, Paradiso F, Orfanelli U, Giordano L, Bussi M, Cenci S, Milan E.
    PLoS One; 2018 Aug; 13(8):e0201621. PubMed ID: 30067838
    [Abstract] [Full Text] [Related]

  • 5. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, Shi H, Duan Z.
    Gynecol Oncol; 2018 Jul; 150(1):143-150. PubMed ID: 29699801
    [Abstract] [Full Text] [Related]

  • 6. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY, Zhang Y, Zhang JJ, Zhang LC, Liu YN, Wu Y, Xue YN, Lu SY, Su J, Sun LK.
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [Abstract] [Full Text] [Related]

  • 7. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.
    Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F, Sun L.
    Eur J Cancer; 2011 Jul; 47(10):1585-94. PubMed ID: 21371883
    [Abstract] [Full Text] [Related]

  • 8. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu LZ, Jiang BH.
    Autophagy; 2015 Jul; 11(2):373-84. PubMed ID: 25650716
    [Abstract] [Full Text] [Related]

  • 9. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
    Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang J, Cui M.
    Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
    [Abstract] [Full Text] [Related]

  • 10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [Abstract] [Full Text] [Related]

  • 11. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q, Yogosawa S, Iizumi Y, Sakai T, Sowa Y.
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. p62 aggregates mediated Caspase 8 activation is responsible for progression of ovarian cancer.
    Yan XY, Zhong XR, Yu SH, Zhang LC, Liu YN, Zhang Y, Sun LK, Su J.
    J Cell Mol Med; 2019 Jun; 23(6):4030-4042. PubMed ID: 30941888
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R, Tortosa A, Martinez-Soler F, Vidal A, Condom E, Pérez-Perarnau A, Ruiz-Larroya T, Gil J, Giménez-Bonafé P.
    Int J Cancer; 2013 Apr 01; 132(7):1525-36. PubMed ID: 22961628
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.
    He Y, Zhu Q, Chen M, Huang Q, Wang W, Li Q, Huang Y, Di W.
    Oncotarget; 2016 Oct 25; 7(43):70803-70821. PubMed ID: 27683123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.